Safety and efficacy of a novel hepatobiliary MR contrast agent GN-1140 (Gd-DTPA-DeA): From the results of phase I and phase II clinical trials

Academic Radiology

Volumn 9, Issue SUPPL. 2, 2002, Pages

  Tanimoto, Akihiro ^a   Kadoya, Masumi ^b   Kawamura, Yasutaka ^c   Kuwatsuru, Ryohei ^d   Gokan, Takehiko ^e   Hirohashi, Shinji ^f  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE 4 DEACYLANILINE; GADOLINIUM PENTETATE DERIVATIVE; GN 1140; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEVER; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM; HUMAN; INJECTION SITE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL NOISE RATIO; ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER TUMOR; MALE; MIDDLE AGED;

ADULT; AGED; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 0036333540     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)80262-3     Document Type: Conference Paper

References (1)

1. Results of an early phase II clinical trial with GN-1140 (Gd-DTPA-DeA), a novel hepatobiliary MR contrast agent for imaging liver tumors in Japan